MediciNova (NASDAQ:MNOV – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare MediciNova to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, institutional ownership and dividends.
Valuation & Earnings
This table compares MediciNova and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MediciNova | $935,717.00 | -$12.00 million | -6.24 |
| MediciNova Competitors | $18.73 billion | $3.24 billion | 560.54 |
MediciNova’s rivals have higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares MediciNova and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediciNova | -1,126.60% | -26.47% | -24.24% |
| MediciNova Competitors | -2,391.71% | -204.89% | -14.89% |
Volatility & Risk
MediciNova has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, MediciNova’s rivals have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Institutional and Insider Ownership
9.9% of MediciNova shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.0% of MediciNova shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for MediciNova and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediciNova | 1 | 1 | 4 | 1 | 2.71 |
| MediciNova Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
MediciNova currently has a consensus price target of $7.75, suggesting a potential upside of 491.60%. As a group, “Pharmaceuticals” companies have a potential upside of 30.30%. Given MediciNova’s stronger consensus rating and higher possible upside, equities research analysts plainly believe MediciNova is more favorable than its rivals.
Summary
MediciNova beats its rivals on 7 of the 13 factors compared.
About MediciNova
MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.
